- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT05404880
Étude INSPIRIS Chine PMCF (INSPIRIS China)
Étude de suivi clinique post-commercialisation de la valve aortique INSPIRIS RESILIA d'Edwards Lifesciences dans la population chinoise
The objective of this post-market trial is to evaluate long term safety and performance of the Edwards Lifesciences INSPIRIS RESILIA aortic valve in Chinese patients in a real-world clinical setting.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
The trial is a multi-center, prospective, single-arm study that will implant up to 250 subjects with the Edwards INSPIRIS RESILIA aortic valve and will continue to follow and assess them after implant for 5 years. In an effort to obtain sufficient long-term data, all subjects will be asked to reconsent to extended follow-up through 10 years.
Type d'étude
Inscription (Réel)
Contacts et emplacements
Lieux d'étude
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, Chine, 100037
- Fuwai Hospital, CAMS & PUMC
-
Beijing, Beijing Municipality, Chine, 100029
- Beijing Anzhen Hospital, Capital Medical University
-
-
Fujian
-
Xiamen, Fujian, Chine, 361008
- Xiamen Cardiovascular Hospital Xiamen University
-
-
Guangdong
-
Guangzhou, Guangdong, Chine, 510080
- The First Affiliated Hospital, Sun Yat-sen University
-
Shenzhen, Guangdong, Chine, 518038
- Fuwai Hospital Chinese Academy of Medical Sciences, Shenzhen
-
-
Henan
-
Zhengzhou, Henan, Chine, 450052
- The First Affiliated Hospital of Zhengzhou University
-
Zhengzhou, Henan, Chine, 450008
- Henan Provincial Chest Hospital
-
Zhengzhou, Henan, Chine, 451460
- Fuwai Central China Cardiovascular Hospital
-
-
Jiangsu
-
Nanjing, Jiangsu, Chine, 210012
- Nanjing First Hospital
-
-
Shaanxi
-
Xi'an, Shaanxi, Chine, 710065
- The First Affiliated Hospital of Xi'an Jiaotong University
-
-
Sichuan
-
Chengdu, Sichuan, Chine, 610072
- Sichuan Academy of Medical Sciences·Sichuan Provincial People's Hospital
-
-
Yunnan
-
Kunming, Yunnan, Chine, 650102
- Fuwai Yunnan Cardiovascular Hospital
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
Méthode d'échantillonnage
Population étudiée
Subjects requiring an elective replacement of their native or prosthetic aortic valve who have agreed to participate in the study.
La description
Inclusion Criteria:
- Subject is 18 years or older
- Subjects requiring an elective replacement of their native or prosthetic aortic valve as indicated per the IFU
- Subject is scheduled to undergo planned aortic valve replacement with or without concomitant coronary bypass surgery, with or without ascending aorta replacement
- Provide signed informed consent prior to the study participation
Exclusion Criteria:
- Valve implantation is contraindicated per the IFU
- Requires planned multiple valve replacement/ repair
- Has active endocarditis/myocarditis prior to the scheduled aortic replacement surgery
- Estimated Life expectancy< 12 months
- Current or recent participation (within 6 weeks prior to surgery) in another drug or device trial
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Modèles d'observation: COHORT
- Perspectives temporelles: PROSPECTIVE
Cohortes et interventions
Groupe / Cohorte |
Intervention / Traitement |
|---|---|
|
EDWARDS INSPIRIS RESILIA Aortic Valve
Subjects who were treated with the INSPIRIS RESILIA aortic heart valve. |
Surgical replacement of the aortic valve with the INSPIRIS RESILIA Aortic Valve. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Subject's Occurrence Rate of Study Valve Related Death
Délai: 10 Years
|
The primary safety endpoint is the percentage of study valve related death which includes death caused by structural valve deterioration, nonstructural dysfunction, valve thrombosis, embolism, bleeding event, or operated valve endocarditis; death related to reintervention on the operated valve; or sudden, unexplained death. |
10 Years
|
|
Subject's Occurrence Rate of Structural Valve Deterioration
Délai: 10 Years
|
The primary safety endpoint is the percentage of Structural Valve Deterioration which includes dysfunction or deterioration involving the operated valve (exclusive of infection or thrombosis), as determined by re-operation, autopsy, or clinical investigation. |
10 Years
|
|
Subject's Occurrence Rate of Re-operation on the Study Valve
Délai: 10 Years
|
The primary safety endpoint is the reoperation rate on the study valve which is any operation that repairs, alters, or replaces the study valve, which occurs after the completion of the procedure and the transfer out of the procedure room. |
10 Years
|
|
Subject's Occurrence Rate of Major Bleeding
Délai: 10 Years
|
The primary safety endpoint is the rate of major bleeding which is any episode of major internal or external bleeding that causes death, hospitalization, or permanent injury (e.g. Vision loss) or necessitates transfusion of 3 or more units of PRBC, pericardiocentesis, or exploration/reoperation for bleeding. |
10 Years
|
|
Subject's Occurrence Rate of Thromboembolic Events
Délai: 10 Years
|
The primary safety endpoint is the rate of thromboembolic events which is an embolic event that occurs in absence of infection (endocarditis) starting from anesthesia time. Embolism may be manifested by a neurologic event (Stroke or Transient Ischemic Attack) or a non-cerebral embolic event. |
10 Years
|
|
Subject's Occurrence Rate of Stroke
Délai: 10 Years
|
The primary safety endpoint is the rate of strokes which is a prolonged (>72 hours) or permanent neurologic deficit that is usually associated with abnormal results of magnetic resonance imaging or computed tomographic scans. |
10 Years
|
|
Subject's Occurrence Rate of Transient Ischemic Attack
Délai: 10 Years
|
The primary safety endpoint is the rate of transient ischemic attacks which is characterized by fully reversible symptoms of short duration. |
10 Years
|
|
Subject's Occurrence Rate of Non-Cerebral Thromboembolism
Délai: 10 Years
|
The primary safety endpoint is the rate of non-cerebral thromboembolism which is an embolus documented operatively, at autopsy, or clinically that produces signs or symptoms attributable to complete or partial obstruction of a peripheral artery (does not include deep vein thrombosis). |
10 Years
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Subject's Average Mean Gradient at 10 Years
Délai: 10 Years
|
Hemodynamic performance - Mean gradients as evaluated by echocardiography |
10 Years
|
|
Subject's Average Peak Gradient at 10 Years
Délai: 10 Years
|
Hemodynamic performance - Peak gradients as evaluated by echocardiography |
10 Years
|
|
Subject's Average Effective Orifice Area at 10 Years
Délai: 10 Years
|
Hemodynamic performance - Effective Orifice Area evaluated by echocardiography |
10 Years
|
|
Subject's Average Effective Orifice Area Index at 10 Years
Délai: 10 Years
|
Hemodynamic performance - Effective Orifice Area Index evaluated by echocardiography |
10 Years
|
|
Amount of Aortic Central Regurgitation in Subjects at 10 Years
Délai: 10 Years
|
Hemodynamic performance - Aortic central regurgitation evaluated by echocardiography |
10 Years
|
|
Amount of Aortic Paravalvular Regurgitation in Subjects at 10 Years
Délai: 10 Years
|
Hemodynamic performance - Aortic paravalvular regurgitation evaluated by echocardiography |
10 Years
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Les enquêteurs
- Chercheur principal: Hansong Sun, Professor, Chinese Academy of Medical Sciences, Fuwai Hospital
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Autres numéros d'identification d'étude
- 2021-09
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
Individual participant data will not be available to other researchers.
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
produit fabriqué et exporté des États-Unis.
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .